Utility of the trabecular bone score (TBS) in secondary osteoporosis.

Détails

Ressource 1Télécharger: 75.pdf (1681.29 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_F767CD132E96
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Utility of the trabecular bone score (TBS) in secondary osteoporosis.
Périodique
Endocrine
Auteur⸱e⸱s
Ulivieri F.M., Silva B.C., Sardanelli F., Hans D., Bilezikian J.P., Caudarella R.
ISSN
1559-0100 (Electronic)
ISSN-L
1355-008X
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
47
Numéro
2
Pages
435-448
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
Altered bone micro-architecture is an important factor in accounting for fragility fractures. Until recently, it has not been possible to gain information about skeletal microstructure in a way that is clinically feasible. Bone biopsy is essentially a research tool. High-resolution peripheral Quantitative Computed Tomography, while non-invasive, is available only sparsely throughout the world. The trabecular bone score (TBS) is an imaging technology adapted directly from the Dual Energy X-Ray Absorptiometry (DXA) image of the lumbar spine. Thus, it is potentially readily and widely available. In recent years, a large number of studies have demonstrated that TBS is significantly associated with direct measurements of bone micro-architecture, predicts current and future fragility fractures in primary osteoporosis, and may be a useful adjunct to BMD for fracture detection and prediction. In this review, we summarize its potential utility in secondary causes of osteoporosis. In some situations, like glucocorticoid-induced osteoporosis and in diabetes mellitus, the TBS appears to out-perform DXA. It also has apparent value in numerous other disorders associated with diminished bone health, including primary hyperparathyroidism, androgen-deficiency, hormone-receptor positive breast cancer treatment, chronic kidney disease, hemochromatosis, and autoimmune disorders like rheumatoid arthritis. Further research is both needed and warranted to more clearly establish the role of TBS in these and other disorders that adversely affect bone.
Pubmed
Web of science
Création de la notice
03/02/2015 15:38
Dernière modification de la notice
09/09/2021 7:15
Données d'usage